Puma Biotechnology Profit Margin

The latest profit margin for PBYI is 11.52% as of June 2026. That compares with 22.68% in the prior-year period — down 49.2% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Puma Biotechnology's historical trend and sector peers before judging valuation or financial health.

Over the past year, PBYI's profit margin moved from 22.68% to 11.52% — a 49.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Puma Biotechnology's valuation or profitability profile.

Against Healthcare companies, PBYI currently prints 11.52% for profit margin, while the sector average sits near 14.34%. That is roughly 19.7% below the sector mean. Large gaps often invite a closer look at Puma Biotechnology's growth, margins, and balance sheet.

Profit Margin shows how effectively Puma Biotechnology converts resources into returns. At 11.52%, PBYI may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 22.68% in the prior-year period — down 49.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting PBYI's profit margin (11.52%), review year-over-year change from 22.68%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.